Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2025)

NewAmsterdam Pharma's FCF Margin history spans 3 years, with the latest figure at 128046.88% for Q4 2025.

  • For Q4 2025, FCF Margin fell 12775339.0% year-over-year to 128046.88%; the TTM value through Dec 2025 reached 657.82%, down 30833.0%, while the annual FY2025 figure was 657.82%, 30833.0% down from the prior year.
  • FCF Margin for Q4 2025 was 128046.88% at NewAmsterdam Pharma, down from 9428.45% in the prior quarter.
  • Across five years, FCF Margin topped out at 43.2% in Q3 2024 and bottomed at 128046.88% in Q4 2025.
  • The 3-year median for FCF Margin is 1652.32% (2023), against an average of 12777.5%.
  • The largest annual shift saw FCF Margin surged 382569bps in 2024 before it crashed -12775339bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 4119.18% in 2023, then skyrocketed by 93bps to 293.49% in 2024, then crashed by -43530bps to 128046.88% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's FCF Margin are 128046.88% (Q4 2025), 9428.45% (Q3 2025), and 197.23% (Q2 2025).